Matthew A. Curry
Beth Israel Deaconess Medical Center(US)Harvard University(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Stress Responses and Cortisol, HER2/EGFR in Cancer Research, Cancer therapeutics and mechanisms, Crystallization and Solubility Studies
Most-Cited Works
- → Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)(2016)89 cited
- → Non-Peptide Corticotropin-Releasing Hormone Antagonists: Syntheses and Structure−Activity Relationships of 2-Anilinopyrimidines and -triazines(1999)74 cited
- → Synthesis, Corticotropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo-, Imidazo-, and Pyrrolopyrimidines and -pyridines(1999)63 cited
- → A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779(2012)62 cited
- → Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity(2010)49 cited
- → Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase(2012)39 cited
- → In vivo inhibition of Bruton Tyrosine Kinase (BTK) protects against alcoholic liver disease(2021)
- → CCDC 1945928: Experimental Crystal Structure Determination(2019)
- → Triazolopyridine-based Inhibitor of Janus Kinase 2(2012)
- → CCDC 2014674: Experimental Crystal Structure Determination(2020)